Skip to content

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Safety, pharmacokinetics and pharmacodynamics of ICP-332, an oral TYK2 inhibitor, in healthy participants: a randomized, double-blind, placebo-controlled phase I study

ICP-332 is a novel, orally administered TYK2 inhibitor with high selectivity, intended for the treatment of immune inflammatory diseases such as atopic dermatitis, psoriatic arthritis, inflammatory bowel disease and lupus. This Phase I study assessed its safety, pharmacokinetics, pharmacodynamics, and food effect i...

Heng-Li Zhao, Yi-Lin Wei, Yu Jiang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.